LH Stock Recent News
LH LATEST HEADLINES
LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C. , Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients.
First-and-only test of its kind approved under new European Union regulations expands access to personalized cancer care for patients across the EU BURLINGTON, N.C. , July 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today PGDx elio™ tissue complete has been CE-marked under the European Union's (EU) new In Vitro Diagnostic Regulation (IVDR).
Labcorp Holdings Inc. LH on Thursday reported stronger-than-expected results for the second quarter.
Labcorp Holdings Inc. (NYSE:LH ) Q2 2025 Earnings Conference Call July 24, 2025 9:00 AM ET Company Participants Adam H. Schechter - President, CEO & Chairman Christin O'Donnell - Vice President of Investor Relations Julia A.
Labcorp Holdings (LH) came out with quarterly earnings of $4.35 per share, beating the Zacks Consensus Estimate of $4.14 per share. This compares to earnings of $3.94 per share a year ago.
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Labcorp Holdings Inc. LH, or Labcorp's strong focus on key areas such as oncology, women's health, autoimmune disease and neurology is poised to help it grow in the upcoming quarters. The company maintains a steady pipeline of potential deals that support its financial strategy and will enhance its organic growth.
LOS ANGELES, June 02, 2025 (GLOBE NEWSWIRE) -- InStride , a leading provider of strategic education and skilling solutions, has facilitated a unique partnership between Arizona State University's College of Health Solutions and Labcorp, a global leader of innovative and comprehensive laboratory services, to launch a Master of Science in Cytology. ASU's online graduate program addresses the severe shortage of cytotechnologists—specialists essential to cancer detection and diagnostics.